Vincamine

SKU: orb1226046

Description

Vincamine is a peripheral vasodilator, that increases blood flow to the brain.(In Vitro):Vincamine (20, 40 and 80 μM; 24 hours) exerts a signi cant, concentration-dependent protective effect in LPS-treated human corneal epithelial cells (HCECs) cells.Vincamine (20, 40 and 80 μM; 24 hours) significantly reduces ROS level in a dose-dependent manner in LPS-treated human corneal epithelial cells (HCECs)cells. Additionally, after Vincamine administration, the levels of MDA is also significantly reduced while the levels of T-AOC, and SOD are increased in a dose-dependent manner.Vincamine (20, 40 and 80 μM; 24 hours) rescues TrxR activity in a dose-dependent manner in HCECs. However, the intracellular activities of Trx, GR and GPx are neither inhibited nor activated by both LPS and Vincaminer.Vincamine could activate GPR40 (EC50=6.28 μM) with DHA (GPR40 ligand) as a positive control (EC50=3.85 μM) in hGPR40-CHO cells.(In Vivo):Vincamine (intraperitoneal injection; 15 and 30 mg/kg/day; 6 weeks) improves glucose tolerance in type 2 diabetic model mice. It effectively lowers the levels of fasting blood glucose and glycated hemoglobin. At the same time, it ameliorates oral glucose tolerance and elevated glucose-induced plasma insulin concentration without influence on basal insulin secretion in vivo.

Key Properties

• CAS Number: 1617-90-9
• MW: 354.44
• Purity: >98% (HPLC)
• Formula: C₂₁H₂₆N₂O₃
• SMILES: O[C@@](C1)(C(OC)=O)N2C3=C(C=CC=C3)C4=C2[C@@]([C@@]1(CC)CCC5)([H])N5CC4
• Target: Others
• Solubility: Water: 62 mg/L

Bioactivity

• In Vivo:
  Vincamine (intraperitoneal injection; 15 and 30 mg/kg/day; 6 weeks) improves glucose tolerance in type 2 diabetic model mice. It effectively lowers the levels of fasting blood glucose and glycated hemoglobin. At the same time, it ameliorates oral glucose tolerance and elevated glucose-induced plasma insulin concentration without influence on basal insulin secretion In vivo.
• In Vitro:
  Vincamine (20, 40 and 80 μM; 24 hours) exerts a signi cant, concentration-dependent protective effect in LPS-treated human corneal epithelial cells (HCECs) cells. Vincamine (20, 40 and 80 μM; 24 hours) significantly reduces ROS level in a dose-dependent manner in LPS-treated human corneal epithelial cells (HCECs)cells. Additionally, after Vincamine administration, the levels of MDA is also significantly reduced while the levels of T-AOC, and SOD are increased in a dose-dependent manner. Vincamine (20, 40 and 80 μM; 24 hours) rescues TrxR activity in a dose-dependent manner in HCECs. However, the intracellular activities of Trx, GR and GPx are neither inhibited nor activated by both LPS and Vincaminer. Vincamine could activate GPR40 (EC50 = 6.28 μM) with DHA (GPR40 ligand) as a positive control (EC50 = 3.85 μM) in hGPR40-CHO cells.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Angiopac | Devincan | Equipur | Minorin | NSC 91998 | Novicet

Quick Database Links

Gene Symbol

Others